Merck & Co., Inc. (NYSE:MRK) Stock Holdings Lifted by Traynor Capital Management Inc.

Traynor Capital Management Inc. grew its position in Merck & Co., Inc. (NYSE:MRKGet Rating) by 2.0% during the 1st quarter, HoldingsChannel.com reports. The firm owned 9,727 shares of the company’s stock after acquiring an additional 194 shares during the quarter. Traynor Capital Management Inc.’s holdings in Merck & Co., Inc. were worth $798,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Bromfield Sneider Wealth Advisors acquired a new position in Merck & Co., Inc. in the first quarter worth approximately $79,000. ACG Wealth increased its stake in shares of Merck & Co., Inc. by 5.6% during the 1st quarter. ACG Wealth now owns 13,523 shares of the company’s stock worth $1,110,000 after purchasing an additional 722 shares during the last quarter. WealthBridge Investment Counsel Inc. raised its holdings in shares of Merck & Co., Inc. by 4.1% during the 1st quarter. WealthBridge Investment Counsel Inc. now owns 87,820 shares of the company’s stock valued at $7,206,000 after purchasing an additional 3,475 shares in the last quarter. Captrust Financial Advisors lifted its stake in shares of Merck & Co., Inc. by 3.8% in the 3rd quarter. Captrust Financial Advisors now owns 300,309 shares of the company’s stock valued at $22,756,000 after purchasing an additional 11,068 shares during the last quarter. Finally, Beech Hill Advisors Inc. boosted its holdings in Merck & Co., Inc. by 0.8% in the fourth quarter. Beech Hill Advisors Inc. now owns 77,934 shares of the company’s stock worth $5,973,000 after purchasing an additional 581 shares in the last quarter. 72.88% of the stock is owned by institutional investors.

A number of analysts have weighed in on the company. Barclays boosted their price target on Merck & Co., Inc. from $94.00 to $97.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 12th. Mizuho assumed coverage on Merck & Co., Inc. in a report on Friday, April 1st. They issued a “buy” rating and a $100.00 target price for the company. SVB Leerink reiterated an “outperform” rating and set a $102.00 price target on shares of Merck & Co., Inc. in a report on Monday, June 6th. Morgan Stanley reduced their price objective on shares of Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 6th. Finally, StockNews.com assumed coverage on shares of Merck & Co., Inc. in a research note on Thursday, March 31st. They issued a “strong-buy” rating on the stock. Seven analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.60.

Shares of MRK stock opened at $89.16 on Thursday. The stock has a market cap of $225.47 billion, a P/E ratio of 15.95, a price-to-earnings-growth ratio of 1.19 and a beta of 0.36. Merck & Co., Inc. has a 1 year low of $70.89 and a 1 year high of $94.92. The company has a current ratio of 1.40, a quick ratio of 1.14 and a debt-to-equity ratio of 0.75. The stock has a 50 day simple moving average of $88.75 and a 200 day simple moving average of $82.17.

Merck & Co., Inc. (NYSE:MRKGet Rating) last issued its earnings results on Thursday, April 28th. The company reported $2.14 EPS for the quarter, topping the consensus estimate of $1.81 by $0.33. Merck & Co., Inc. had a return on equity of 47.86% and a net margin of 26.27%. The firm had revenue of $15.90 billion during the quarter, compared to the consensus estimate of $14.64 billion. During the same quarter in the previous year, the firm earned $1.40 earnings per share. The business’s quarterly revenue was up 31.6% on a year-over-year basis. Analysts forecast that Merck & Co., Inc. will post 7.32 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 8th. Shareholders of record on Wednesday, June 15th will be issued a dividend of $0.69 per share. The ex-dividend date is Tuesday, June 14th. This represents a $2.76 dividend on an annualized basis and a yield of 3.10%. Merck & Co., Inc.’s payout ratio is currently 49.37%.

Merck & Co., Inc. Profile (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.